Kynurenine

Kynurenine

SCHEMBL288988

Nc1ccccc1C(=O)CC(N)C(=O)O.Nc1ccccc1C(=O)CC(N)C(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.64
▸ HIF1A Q16665 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ KYNU Q16719 2/20 0.49
▸ GAA P10253 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ALPI P09923 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ XIAP P98170 1/20 0.47
▸ SLC7A5 Q01650 1/20 0.47
▸ KMO O15229 3/20 0.45
▸ SLC1A3 P43003 2/20 0.45
▸ SLC1A2 P43004 2/20 0.45
▸ SLC1A1 P43005 2/20 0.45
▸ GRM2 Q14416 1/20 0.45
▸ GRM3 Q14832 1/20 0.45
▸ GRIK1 P39086 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Kynurenine SCHEMBL29415716 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL288254 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL29349989 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL20874 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL29396313 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL20875 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL288989 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
Kynurenine SCHEMBL2181581 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL13969610 1.00 KDM4E (0.64) KDM4EHIF1ATDP1KYNUGAA
L-Kynurenine SCHEMBL2368794 0.98 KDM4E (0.62) KDM4EHIF1ATDP1KYNUGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 — — WO disclosed
US-20230086254-A1 MEDICINAL COMPOSITION COMPRISING DENTAL PULP-DERIVED CELLS JCR PHARMACEUTICALS CO., LTD. (JP) 2023-03-23 — — US disclosed
WO-2018134329-A1 METABOLIC BIOMARKER SET FOR ASSESSING OVARIAN CANCER BIOCRATES LIFE SCIENCES AG (AT) 2018-07-26 — — WO disclosed
EP-3191845-A1 BIOMARKERS FOR ASSESSING BREAST CANCER IDCGS Clínica de Diagnósticos Médicos Ltda (BR) 2017-07-19 — — EP disclosed
EP-3126841-A1 BIOMARKERS FOR ASSESSING HIV IDCGS clinica de Diagnosticos Medicos (BR) 2017-02-08 — — EP disclosed
WO-2016038157-A1 BIOMARKERS FOR ASSESSING BREAST CANCER IDCGS CLÍNICA DE DIAGNÓSTICOS MÉDICOS LTDA (BR) 2016-03-17 — — WO disclosed
WO-2015150360-A1 BIOMARKERS FOR ASSESSING HIV IDCGS CLINICA DE DIAGNOSTICOS MEDICOS (BR) 2015-10-08 — — WO disclosed
CN-104487457-A Target tissue specific antigen binding molecules CHUGAI PHARMACEUTICAL CO LTD 2015-04-01 — — CN disclosed
WO-2012113834-A1 METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS OF INFLAMMATORY BRAIN INJURY IN PRETERM BORN INFANTS BIOCRATES LIFE SCIENCES AG (AT) 2012-08-30 — — WO disclosed
EP-2427773-A1 METHOD OF DIAGNOSING ASPHYXIA Keller, Matthias (DE) 2012-03-14 — — EP disclosed
WO-2011062628-A1 METHODS AND COMPOSITIONS FOR MODULATION OF T CELLS VIA THE KYNURENINE PATHWAY NEW YORK UNIVERSITY (US) 2011-05-26 — — WO disclosed
WO-2010128054-A1 METHOD OF DIAGNOSING ASPHYXIA BIOCRATES LIFE SCIENCES AG (AT) 2010-11-11 — — WO disclosed
Send feedback